Table 2.
Factors | Difference of means | 95% CI | P value | |
Lower | Upper | |||
Age | ||||
< 63 years old (vs > 80 years old) | −4.33 | −6.21 | −2.45 | <0.001 |
Location | ||||
Northeast (vs Midwest) | 4.26 | 2.54 | 5.98 | <0.001 |
Midwest (vs South) | 5.99 | 4.21 | 7.76 | <0.001 |
South (vs Northeast) | 1.73 | 0.51 | 2.94 | 0.005 |
Disease | ||||
AMD (vs RVO) | 1.29 | −0.22 | 2.79 | 0.093 |
DMO/DR (vs AMD) | 1.63 | −0.93 | 2.18 | 0.028 |
RVO (vs DMO/DR) | −1.66 | −2.31 | 0.99 | 0.042 |
Time of Diagnosis | ||||
< 5 years (vs > 5 years) | −0.85 | −2.25 | 0.54 | 0.23 |
Frequency of treatment | ||||
Every 4–5 weeks (vs every 10–16 weeks) | −1.58 | −3.27 | 0.11 | 0.066 |
Every 10–16 weeks (vs PRN) | 0.83 | −2.24 | 3.9 | 0.596 |
PRN (vs every 4–5 weeks) | −0.75 | −3.62 | 2.12 | 0.608 |
Total number of injections | ||||
< 10 (vs > 50) | −1.44 | −3.4 | 0.51 | 0.148 |
Patients with no missing data for any of the variables were included in the regression analysis; n=1120.
P value < 0.05 considered to be significant.
AMD, age-related macular degeneration; DMO, diabetic macular oedema; DR, diabetic retinopathy; PRN, pro re nata; RVO, retinal vein occlusion.